Advances in the Extracellular Vesicles Treatment of Alopecia

This study found that platelet-rich plasma therapy significantly improved hair density and reduced hair shedding in Vietnamese patients with androgenetic alopecia, with high patient satisfaction and minimal side effects.

This open-label study found that combining exosome therapy with microneedling significantly improved hair density and patient satisfaction for male patients with mild to moderate androgenetic alopecia, with most reporting noticeable improvements and only mild, transient side effects after 12 months.

This study found that extracellular vesicles derived from hyaluronic acid-stimulated induced pluripotent stem cells significantly improved hair growth in a model of androgenetic alopecia in mice by enhancing Wnt/β-catenin signaling and regulating androgen receptor activity, showing comparable results to the commonly used treatment finasteride.

In this study, injecting foreskin-derived mesenchymal stromal cell exosomes into the scalps of men with androgenetic alopecia significantly increased hair density and patient satisfaction without side effects over a 12-week period.

This study found that treating patients with androgenetic alopecia using exosomes from adipose tissue stem cells over 24 weeks significantly increased hair density and patient satisfaction without severe adverse effects, suggesting a promising alternative treatment for hair loss.

This case study suggests that rose stem cell-derived exosomes, administered via noninvasive electroporation, may promote hair regeneration in androgenetic alopecia; larger studies are needed to confirm these findings.

This article provides a detailed analysis of exosome therapy as a novel treatment for hair loss, discussing its potential benefits, limitations, and the importance of standardized research reporting as human research remains limited.

This review highlights the potential of exosomes, particularly their microRNA components, as promising candidates for developing effective hair loss treatments by exploring their roles in hair follicle development and regeneration.

This study investigated the effects of exosomes from human umbilical cord mesenchymal stem cells on hair loss in mice with alopecia areata, emphasizing the potential of these easily isolated and stored exosomes for research and clinical treatment.

This study found that while clinical evidence is limited, early preclinical results suggest exosome treatment may enhance hair growth and warrant further research for therapeutic use in alopecia.

This review found that while preclinical studies highlight the potential benefits of exosome therapeutics for hair loss, clinical evidence on their safety and effectiveness for alopecia is currently lacking, requiring further research.

This study found that exosomal miR-181a-5p promotes hair follicle growth and development in vitro by activating the Wnt/β-catenin signaling pathway and suppressing hair follicle stem cell apoptosis.

This abstract provides information about data availability and author affiliations but does not contain results or conclusions from the study itself.

This study found that early passage dermal papilla cell-derived extracellular vesicles, combined with specialized medium, helped adipose-derived stem cells develop dermal papilla-like properties.

In this study, intradermal injections of extracellular vesicles over six months were reported to be safe and effective in improving hair growth among patients with pattern hair loss, with favorable response linked to specific patient factors and treatment volumes.

This study found that macrophage-engineered extracellular vesicle mimetics may promote hair regrowth, presenting a potential alternative to extracellular vesicles for overcoming clinical production challenges.

This study reports that hair follicle-derived mesenchymal stem cells significantly reduced hair loss and inflammation in alopecia areata models, suggesting a potential therapeutic approach.

This review explains the evolution and current techniques of follicular unit transplantation for hair restoration, identifying conditions suitable for surgery and offering guidelines for dermatologists to assess candidate suitability, focusing on male and female pattern hair loss.

This study reviewed the literature on low-dose oral minoxidil as a primary treatment for various hair loss disorders, concluding that it is a successful and well-tolerated alternative to topical minoxidil for patients with poor adherence to other therapies.

In this study, exosome-mimetic nanovesicles derived from neural progenitor cells promoted hair follicle regeneration in mice by activating the Wnt/β-catenin signaling pathway.

This study found that extracellular vesicles from low-passage dermal papilla cells may activate hair growth by delivering miR-140-5p, which downregulates BMP2 signaling, suggesting potential therapeutic targets for alopecia.

Dermal exosomes with miR-218-5p boost hair growth by controlling β-catenin signaling.

This study reviews advancements in hair restoration surgery, noting that follicular unit excision significantly improves outcomes by enabling graft harvesting without scarring and reporting a graft transection rate under 4% when conducted with advanced equipment.

This article discusses the advancements in follicular unit transplantation for hair restoration and reports no clinical results; it emphasizes improved aesthetic outcomes using updated techniques.

This study found that both FUE and FUT methods are equally effective in producing high-quality hair grafts, with FUE offering the advantage of less noticeable scarring compared to FUT.

This review discusses pharmacologic and non-pharmacologic treatments for androgenetic alopecia, noting that current medications like finasteride and minoxidil can slow hair loss but only partially restore hair growth, with early treatment offering better outcomes.

This study demonstrated that OSA hydrogels enhanced the stability and retention of dermal papilla-derived extracellular vesicles, which significantly improved hair regeneration in both cultured human hair and a mouse depilation model.

This study found that extracellular vesicles from stimulated human dermal fibroblasts enhanced hair follicle growth ex vivo by activating dermal papilla cells and involving the Norrin and β-catenin pathways.

In a mouse model, this study demonstrated that a microneedle patch system using keratin and integrated with MSC-derived exosomes and UK5099 promoted hair regrowth more efficiently than traditional delivery methods.

This study suggests that exosomes derived from dermal papilla cells, especially those cultured in three dimensions, promote hair growth and regeneration by enhancing follicular cell activity.

This study demonstrated that enhancing human skin constructs with hair follicles through engineered cell organization and vascularization improved hair growth in immunodeficient mice, suggesting potential advances for treating alopecia and chronic wounds.

This abstract does not present new clinical findings or a research study.

This study found that platelet-rich plasma significantly increased hair count, density, and the percentage of anagen hairs in patients with androgenetic alopecia, but these improvements did not correlate with platelet or growth factor levels.

This review examines the FDA's 510(k) approval process for low-level laser therapy devices used in treating androgenetic alopecia and reports no new clinical findings.

In this study, dermal papilla cell-derived exosomes accelerated hair follicle growth in mice, suggesting potential for treating hair loss by modulating key signaling pathways.

This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

This study found that treatment with mesenchymal stem cell extracellular vesicles enhanced hair growth in mice and stimulated dermal papilla cell activity and growth factor production in vitro.

This review discusses the potential of adipose-derived stem cells for hair regeneration and suggests that these cells and their conditioned media may offer a promising strategy for treating hair loss.

This review discusses various aspects of hair follicle biology and highlights unresolved questions and potential new research avenues, but presents no new experimental findings.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This review discusses current experimental approaches for regenerating human hair follicles using tissue engineering and isolated cells, but reports no successful strategies with adult cells yet found.

This review discusses the efficacy and safety of 5-alpha reductase inhibitors for treating androgenetic alopecia, noting concerns about sexual side effects, which are typically uncommon and often resolve over time.

This review concluded that oral finasteride for men and topical minoxidil for both genders have the most evidence supporting their effectiveness and safety for treating androgenetic alopecia.

This study found that intradermal adipocyte lineage cells in mice are necessary and sufficient to activate follicular stem cells, highlighting their role in regulating skin stem cell activity.

This study found that subcutaneous administration of conditioned medium from adipose-derived stem cells promoted hair growth in mice, and hypoxia enhanced this effect by altering growth factor secretion.

This study found that minoxidil topical solution was associated with a dose-related occurrence of hypertrichosis, especially facial hair, in women treated for androgenetic alopecia.